Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

The effect of interferon-alpha-2b therapy on humoral immunity after COVID-19 infection

Albina Hasanova, Mikhail Kostinov, Irina Solov’ Ova, Olga Kalinovskaya, Pradeep Baghel, Maksim Abdulkin
ERJ Open Research 2022 8: 223; DOI: 10.1183/23120541.LSC-2022.223
Albina Hasanova
1-, Ulyanovsk , Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: albinafeizer@yandex.ru
Mikhail Kostinov
2-, Moscow, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irina Solov’ Ova
1-, Ulyanovsk , Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olga Kalinovskaya
1-, Ulyanovsk , Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pradeep Baghel
1-, Ulyanovsk , Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maksim Abdulkin
1-, Ulyanovsk , Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Salivary IgA is an available marker of mucosal immunity and may be useful in assessing the immune response. Correction of adverse effects after coronavirus infection can be achieved with the use of interferon-alpha-2b therapy.

Aim: To study and evaluate changes in the level of secretory IgA in saliva sample of patients who underwent COVID-19 before and after interferon-alpha-2b therapy.

Methods: Saliva samples from 65 patients aged 18 to 65 years after COVID-19 with a disease duration of up to 6 months. In our study 83,0% (n=54) of adults were women, the average age in the group was 48±1,61 years. Levels of sIgA were determined by enzyme immunoassay (ELISA) before the use of interferon-alpha-2b and 1 month after preventive therapy (topically on the nasal mucosa).

Results: In patients after coronavirus infection a decrease in the level of the initial sIgA in saliva samples to 2,34 ± 0,3 pg/ml was detected, compared with the conditional norm of 3,5-12 pg/ml. After therapy with interferon-alpha-2b, an increase in the level of secretory IgA was noted by almost 2 times, which was 4,62± 1,13 pg/ml.

Conclusion: When administration interferon-alpha-2b during the rehabilitation period in patients who underwent COVID-19, nonspecific stimulation of mucosal immunity was established, which is accompanied by normalization of the level of sIgA in saliva.

  • Immunology
  • Covid-19
  • Pharmacology

Footnotes

Cite this article as ERJ Open Research 2022; 8: Suppl. 8, 223.

This article was presented at the 2022 ERS Lung Science Conference, in session “Poster Session 2”.

This is an ERS Lung Science Conference abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

  • Copyright ©the authors 2022
Previous
Back to top
Vol 8 Issue suppl 8 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The effect of interferon-alpha-2b therapy on humoral immunity after COVID-19 infection
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The effect of interferon-alpha-2b therapy on humoral immunity after COVID-19 infection
Albina Hasanova, Mikhail Kostinov, Irina Solov’ Ova, Olga Kalinovskaya, Pradeep Baghel, Maksim Abdulkin
ERJ Open Research Mar 2022, 8 (suppl 8) 223; DOI: 10.1183/23120541.LSC-2022.223

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The effect of interferon-alpha-2b therapy on humoral immunity after COVID-19 infection
Albina Hasanova, Mikhail Kostinov, Irina Solov’ Ova, Olga Kalinovskaya, Pradeep Baghel, Maksim Abdulkin
ERJ Open Research Mar 2022, 8 (suppl 8) 223; DOI: 10.1183/23120541.LSC-2022.223
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Phenotype and function of innate lymphoid cells in a murine model of impaired muco-ciliary clearance challenged with allergen
  • Monocyte migratory signatures identify acute and convalescent COVID-19 patients, and are associated with long COVID-19 symptoms
  • Polymeric immunoglobulin receptor and immunoglobulin A system in an eosinophilic mouse model of chronic rhinosinusitis
Show more Allergy and immunology

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2023 by the European Respiratory Society